NCT07227870 2026-03-09
L19IL2/TNF in Patients With Basal Cell Carcinoma
Philogen S.p.A.
Phase 2 Not yet recruiting
Clinical Trials
23 trialsNCT06422936 2026-01-26
SPOTLIGHT204
Highlight Therapeutics
Phase 2 Active not recruiting
NCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT06344052 2024-09-20
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Stamford Pharmaceuticals, Inc.
Phase 2 Recruiting
NCT04893486 2024-08-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Palvella Therapeutics, Inc.
Phase 2 Completed
NCT04669808 2024-03-18
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Sirnaomics
Phase 2 Completed
NCT04362722 2023-10-10
DUNCAN
Philogen S.p.A.
Phase 2 Unknown
NCT04155190 2023-05-31
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Sol-Gel Technologies, Ltd.
Phase 2 Terminated
NCT02354261 2020-08-05
Open-label Trial of SUBAâ„¢-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
HedgePath Pharmaceuticals, Inc.
Phase 2 Completed
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT01898598 2017-05-08
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Terminated
NCT00961896 2015-11-03
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Novartis
Phase 2 Completed
NCT01033019 2015-10-30
To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)
Novartis
Phase 2 Terminated
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed
NCT00833417 2015-05-20
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00108121 2015-01-19
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
Peplin
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT01201915 2014-06-24
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00108134 2008-12-24
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
Peplin
Phase 2 Completed